To validate the therapeutic effect of B6‐RES‐OPC‐HA NPs on AD, we used APP/PS1 Alzheimer's mice for experiments, where mice were injected with B6‐RES‐OPC‐HA NPs at a dose of 1 mg/kg three times a week for 4 weeks (Figure 5a). Here, APP is linked to Alzheimer disease.